Vascular Dementia Market Report 2026

Vascular Dementia Market Overview

• Vascular Dementia market size has reached to $3.27 billion in 2025 • Expected to grow to $5.63 billion in 2030 at a compound annual growth rate (CAGR) of 11.4% • Growth Driver: Rising Prevalence Of Cardiovascular Diseases Boosts The Market • Market Trend: Developing Optimized Formulations For Vascular Dementia Treatment • North America was the largest region in 2025.

What Is Covered Under Vascular Dementia Market?

Vascular dementia refers to a type of cognitive decline caused by reduced blood flow to the brain, often due to strokes or other vascular issues, leading to memory loss and impaired thinking. Treatment for vascular dementia focuses on managing underlying vascular conditions, such as controlling high blood pressure, diabetes, and cholesterol, as well as adopting a healthy lifestyle to improve overall brain health and slow disease progression. The main products of vascular dementia are monoclonal antibodies, small molecules, and peptides. Monoclonal antibodies refer to the segment of vascular dementia treatment where antibodies are designed to target specific proteins or molecules related to the disease. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is intended for end users such as hospitals and clinics, rehabilitation centers, and specialty clinics.

What Is The Vascular Dementia Market Growth Forecast?

The vascular dementia market size is expected to see rapid growth in the next few years. It will grow to $5.63 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to increasing aging population, rising investments in neurological drug development, growing adoption of digital health monitoring tools, expansion of precision medicine approaches, increasing focus on long-term cognitive health management. Major trends in the forecast period include increasing focus on early diagnosis of cognitive disorders, rising integration of digital cognitive assessment tools, growing research into vascular-related neurodegeneration, expansion of personalized treatment approaches, enhanced emphasis on preventive care strategies.

Global Vascular Dementia Market Segmentation

1) By Product: Small Molecules / Drugs, Lifestyle And Nutraceutical Interventions, Rehabilitation Therapies 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 3) By End User: Hospitals And Clinics, Rehabilitation Centers, Specialty Clinics Subsegments: 1) By Small Molecules Or Drugs: Antihypertensives, Anti-diabetic agents, Lipid-lowering agents, Anti-inflammatory agents, Neuroprotective small molecules 2) By Lifestyle And Nutraceutical Interventions: Vitamins & Supplements, Omega-3 Or DHA formulations, Antioxidants 3) By Rehabilitation Therapies: Cognitive enhancers, Physical therapy programs, Occupational therapy aids

What Is The Driver Of The Vascular Dementia Market?

The rising prevalence of cardiovascular disease is expected to propel the vascular dementia market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, arrhythmias, and hypertension. The rising prevalence of cardiovascular diseases is driven by factors such as unhealthy lifestyles, poor dietary habits, physical inactivity, increased stress levels, aging populations, and a surge in risk factors such as obesity, diabetes, and hypertension. Cardiovascular disease increases the risk of vascular dementia by impairing blood flow to the brain, leading to cognitive decline and damage to brain cells due to reduced oxygen and nutrient supply. For instance, in September 2024, according to the data published by the British Heart Foundation, a UK-based cardiovascular research charity, in the UK, approximately 7.6 million people are affected by heart and circulatory diseases, with around 4 million males and 3.6 million females living with these conditions. These diseases are responsible for about 27% of all deaths in the UK, translating to over 170,000 deaths annually, or roughly 480 deaths each day, equating to one death every three minutes. Therefore, the rising prevalence of cardiovascular diseases drives the vascular dementia industry.

Key Players In The Global Vascular Dementia Market

Major companies operating in the vascular dementia market are Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix Corp, Cyclerion Therapeutics Inc, CSPC‑NBP Pharma, Johnson & Johnson Services Inc, Materia Medica Holding, Eisai Co Ltd, Shineway Pharmaceutical, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Pfizer Inc, Biogen Inc, Novartis AG, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals, Zydus Cadila, Eli Lilly and Company

Global Vascular Dementia Market Trends and Insights

Major companies operating in the vascular dementia market are focusing on developing novel therapies, such as multimodal therapies, to sustain their position in the market. Multimodal therapies refer to the integration of various treatment approaches, such as medications, physical therapy, and psychological interventions, to treat a condition comprehensively. For instance, in January 2023, Moleac, a Singapore-based biopharmaceutical company, launched CognivAiD an evidence-based treatment specifically designed for vascular dementia (VaD), a condition with limited therapeutic options. This product combines active extracts from ginkgo, ginseng, and saffron, which have been shown to significantly slow cognitive decline in VaD patients. The unique multimodal action of CognivAiD targets key mechanisms of vascular dementia, including vascular protection, vasoregulation, and neuroinflammation. Supported by extensive clinical trials and a strong safety profile, CognivAiD presents a promising new treatment for individuals suffering from VaD.

What Are Latest Mergers And Acquisitions In The Vascular Dementia Market?

In November 2023, Merck, a US-based pharmaceutical company, acquired Caraway Therapeutics, Inc. for an undisclosed amount. Through this acquisition, Merck aims to accelerate the development of innovative small-molecule therapeutics targeting neurodegenerative diseases, including Parkinson's disease and dementia. Caraway Therapeutics Inc. is a US-based biopharmaceutical company that specializes in drug discovery and development for dementia.

Regional Outlook

North America was the largest region in the vascular dementia market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vascular Dementia Market?

The vascular dementia market consists of revenues earned by entities providing services such as diagnosis, treatment, care management, and support for individuals. The market value includes the value of related goods sold by the service provider or included within the service offering. The vascular dementia market includes sales of assistive devices, cognitive enhancers, and diagnostic tools. Values in this market are ‘factory gate’ values, meaning the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including healthcare providers, wholesalers, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vascular Dementia Market Report 2026?

The vascular dementia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vascular dementia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.